Evidently, RFC4 may be a potential downstream target of Nrf2 in AML, and the present findings may offer a novel therapeutic target for clinical application, thus providing a new idea for overcoming Ara-C resistance in clinical practice. The gene discussed is NFE2L2; the disease is acute myeloid leukemia.